Drug intelligence / Profile preview

Zishen Zhuanggu Tablets

Development stage: Unknown
Lead developer: Nanjing University of Chinese Medicine
Administration: Oral

Overview

Zishen Zhuanggu Tablets is a traditional Chinese medicine (TCM) formulation developed by Nanjing University of Chinese Medicine for the treatment of primary osteoporosis. The drug is specifically designed for patients diagnosed with the TCM pattern of liver-kidney deficiency accompanied by blood stasis. Its therapeutic approach involves nourishing the kidneys, strengthening the skeletal system, and promoting blood circulation to improve bone mineral density and alleviate clinical symptoms associated with bone loss. The formulation has been evaluated in randomized, double-blind, placebo-controlled Phase 2 clinical trials in China to establish its safety and efficacy profile in adult populations with primary osteoporosis.

Other names: Zishen Zhuanggu Pian滋肾壮骨片

Beyond the preview

Go deeper on Zishen Zhuanggu Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zishen Zhuanggu Tablets.

Explore the full profile